MabThera Meets Study Primary Endpoint In Improving Disease Symptoms When Used As First Biologic Therapy In Patients With Rheumatoid Arthritis
Jan 29th 2008Drug InformationArthritis
Roche announced that their innovative drug MabThera (rituximab) can be used effectively and safely as first-line biologic therapy to improve the debilitating symptoms of rheumatoid arthritis (RA). The pivotal study, SERENE1, investigated patients suffering from RA who had an inadequate response to methotrexate (MTX) therapy, a commonly used RA drug.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
